１）B型肝炎のHBウイルスキャリアーが、アジア、アフリカと日本、欧米では違いがあります。このことについての英文献、国内文献を探しています。

１）のみですが、以下の文献はいかがでしょうか。

Clin Lab. 2001;47(1-2):51-5.

Hepatitis B--an important public health issue.

Maddrey WC.

abstract

Hepatitis B is one of the most common infectious diseases in the world. It has been estimated that 350 million people worldwide are chronic hepatitis B virus (HBV) carriers. The global prevalence of chronic HBV infection varies widely, from high ( > 8%, e.g., Africa, Asia and the Western Pacific) to intermediate (2-7% e.g., Southern and Eastern Europe) and low (< 2%, e.g., Western Europe, North America and Australia). The predominant routes of transmission vary according to the endemicity of the HBV infection. In areas of high endemicity, perinatal transmission is the main route of transmission, whereas in areas of low endemicity, sexual contact amongst high-risk adults is predominant. Between one-third and one-quarter of people infected chronically with HBV are expected to develop progressive liver disease (including cirrhosis and primary liver cancer). Although mass vaccination programs have begun to control the spread of HBV infection, therapeutic intervention is the only option for those with established chronic HBV-associated liver disease. Until recently, the only treatment for chronic hepatitis B was the immune modulator, interferon (IFN) alpha. However, IFN alpha treatment has several disadvantages; it is expensive, it must be administered by injection, there are side-effects, and IFN alpha is poorly tolerated. Lamivudine, a nucleoside analogue, is the first effective, and well tolerated, oral treatment for chronic hepatitis B. In conclusion, although we are still some way from eradicating or curing chronic hepatitis B, the advent of lamivudine allows new populations to benefit from therapy and helps to address the global public health problem of hepatitis B.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=...

質問としては、(1)、(2)については世界の大まかなキャリア比とその分布を知りたいということでしょうか？

それとも、何故、そのような分布の差が現れたのか、という考察をご希望でしょうか？とりあえず、分布については以下に記載します。

1)Ｂ型肝炎についてです。

リンク先はｐｄｆファイルですが、３９ページにカラーで比率が掲載されたグラフがあります。

http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo...

Ｂ型肝炎一般についても良く記載されていると思います。

2)Ｃ型肝炎キャリアーのＷＨＯの各地域別の比率まとめがTable1に載っています。

http://www.who.int/mediacentre/factsheets/fs164/en/index.html

国別ではなく、ＷＨＯの事務局毎（日本は太平洋：WesternPacific、インドはSouth-east asia）でのまとめなので大まかなのですが、参考になるでしょうか。

韓国のＡＬＴ異常者については分かりません。